Logo image of FBLG

FIBROBIOLOGICS INC (FBLG) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:FBLG - US31573L1052 - Common Stock

0.2596 USD
+0 (+0.43%)
Last: 12/22/2025, 8:00:02 PM
0.2545 USD
-0.01 (-1.96%)
After Hours: 12/22/2025, 8:00:02 PM
Fundamental Rating

0

Taking everything into account, FBLG scores 0 out of 10 in our fundamental rating. FBLG was compared to 530 industry peers in the Biotechnology industry. FBLG may be in some trouble as it scores bad on both profitability and health. FBLG has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year FBLG has reported negative net income.
FBLG had a negative operating cash flow in the past year.
FBLG Yearly Net Income VS EBIT VS OCF VS FCFFBLG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

FBLG has a worse Return On Assets (-211.59%) than 90.00% of its industry peers.
FBLG has a worse Return On Equity (-14800.80%) than 83.77% of its industry peers.
Industry RankSector Rank
ROA -211.59%
ROE -14800.8%
ROIC N/A
ROA(3y)-111.75%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FBLG Yearly ROA, ROE, ROICFBLG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

FBLG does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FBLG Yearly Profit, Operating, Gross MarginsFBLG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, FBLG has more shares outstanding
The debt/assets ratio for FBLG is higher compared to a year ago.
FBLG Yearly Shares OutstandingFBLG Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M
FBLG Yearly Total Debt VS Total AssetsFBLG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -13.80, we must say that FBLG is in the distress zone and has some risk of bankruptcy.
FBLG's Altman-Z score of -13.80 is on the low side compared to the rest of the industry. FBLG is outperformed by 78.68% of its industry peers.
FBLG has a Debt/Equity ratio of 36.58. This is a high value indicating a heavy dependency on external financing.
FBLG has a worse Debt to Equity ratio (36.58) than 83.58% of its industry peers.
Industry RankSector Rank
Debt/Equity 36.58
Debt/FCF N/A
Altman-Z -13.8
ROIC/WACCN/A
WACCN/A
FBLG Yearly LT Debt VS Equity VS FCFFBLG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 -5M -10M

2.3 Liquidity

FBLG has a Current Ratio of 0.78. This is a bad value and indicates that FBLG is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.78, FBLG is doing worse than 89.62% of the companies in the same industry.
A Quick Ratio of 0.78 indicates that FBLG may have some problems paying its short term obligations.
The Quick ratio of FBLG (0.78) is worse than 89.25% of its industry peers.
Industry RankSector Rank
Current Ratio 0.78
Quick Ratio 0.78
FBLG Yearly Current Assets VS Current LiabilitesFBLG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 5M 10M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 45.73% over the past year.
EPS 1Y (TTM)45.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1200%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -13.84% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-39.21%
EPS Next 2Y-3.37%
EPS Next 3Y-5.86%
EPS Next 5Y-13.84%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
FBLG Yearly Revenue VS EstimatesFBLG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 100M 200M 300M 400M
FBLG Yearly EPS VS EstimatesFBLG Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.5 -0.5 1 1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FBLG. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FBLG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FBLG Price Earnings VS Forward Price EarningsFBLG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FBLG Per share dataFBLG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

A cheap valuation may be justified as FBLG's earnings are expected to decrease with -5.86% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.37%
EPS Next 3Y-5.86%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FBLG!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

FIBROBIOLOGICS INC

NASDAQ:FBLG (12/22/2025, 8:00:02 PM)

After market: 0.2545 -0.01 (-1.96%)

0.2596

+0 (+0.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-31 2025-10-31/amc
Earnings (Next)03-30 2026-03-30
Inst Owners7.73%
Inst Owner Change6.03%
Ins Owners8.66%
Ins Owner Change2.26%
Market Cap18.14M
Revenue(TTM)N/A
Net Income(TTM)-18.50M
Analysts82.22
Price Target8.93 (3339.91%)
Short Float %2.25%
Short Ratio0.96
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-11.57%
Min EPS beat(2)-18.56%
Max EPS beat(2)-4.58%
EPS beat(4)1
Avg EPS beat(4)-11.49%
Min EPS beat(4)-24.78%
Max EPS beat(4)1.96%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-14.63%
PT rev (3m)-12.5%
EPS NQ rev (1m)-3.84%
EPS NQ rev (3m)0%
EPS NY rev (1m)-3.46%
EPS NY rev (3m)-5.18%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 145.09
P/tB 145.09
EV/EBITDA N/A
EPS(TTM)-0.48
EYN/A
EPS(NY)-0.37
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0
BVpS0
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -211.59%
ROE -14800.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-111.75%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 36.58
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 160.44%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.78
Quick Ratio 0.78
Altman-Z -13.8
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1200%
EPS Next Y-39.21%
EPS Next 2Y-3.37%
EPS Next 3Y-5.86%
EPS Next 5Y-13.84%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-42.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-157.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-172.96%
OCF growth 3YN/A
OCF growth 5YN/A

FIBROBIOLOGICS INC / FBLG FAQ

Can you provide the ChartMill fundamental rating for FIBROBIOLOGICS INC?

ChartMill assigns a fundamental rating of 0 / 10 to FBLG.


Can you provide the valuation status for FIBROBIOLOGICS INC?

ChartMill assigns a valuation rating of 0 / 10 to FIBROBIOLOGICS INC (FBLG). This can be considered as Overvalued.


What is the profitability of FBLG stock?

FIBROBIOLOGICS INC (FBLG) has a profitability rating of 0 / 10.


How financially healthy is FIBROBIOLOGICS INC?

The financial health rating of FIBROBIOLOGICS INC (FBLG) is 0 / 10.